Literature DB >> 12354136

Dynamics of the plasma concentrations of TSH, FT4 and T3 following thyroxine supplementation in congenital hypothyroidism.

Bert Bakker1, Marlies J E Kempers, Jan J M De Vijlder, David A Van Tijn, Brenda M Wiedijk, Michael Van Bruggen, Thomas Vulsma.   

Abstract

OBJECTIVE: The dynamics of the plasma concentrations of various diagnostic determinants of thyroid function were analysed in children with congenital hypothyroidism (CH) after the start of T4 supplementation. The description of the biochemical dynamics of TSH and free T4 (FT4) during the first period of thyroxine treatment is important to depict the practical outlines of the initial dosage of T4 and dosage adjustments for newborns with variable forms of CH.
DESIGN: A retrospective analysis was performed of frequent plasma TSH, total T4 (T4), FT4 and total T3 (T3) measurements in 30 CH neonates during the first weeks of treatment, treated with initial daily T4 dosages ranging from 4.8 to 11.1 microg/kg.
RESULTS: A 50% reduction in the initial plasma TSH concentration was achieved after 3-4 days of treatment, independent of CH severity. At a median of 32 days after the start of T4 supplementation, plasma TSH ranged between 0.4 and 4.0 mU/l. The mean interval needed for FT4 to reach the age-related normal values (12-29 pmol/l) was 3 days. The increase in plasma T3 concentrations levelled off within a few days, when T4 reached concentrations of around 100 nmol/l.
CONCLUSIONS: Plasma T3 and FT4 concentrations reach the normal range a few days after thyroxine treatment is started. By contrast, normalization of plasma TSH concentration takes several weeks. At the time that plasma TSH is normalized, CH neonates show a higher range of plasma FT4 concentrations than the normal range. When TSH normalization is the goal of treatment in CH, the target range for plasma FT4 during treatment in the first months needs to be adapted. During the first month of treatment the plasma TSH concentration is not helpful in assessing the proper T4 supplementation dosage. Once plasma TSH has reached normal values, it becomes a reliable determinant in addition to plasma FT4.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354136     DOI: 10.1046/j.1365-2265.2002.01632.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  A rare case of dyshormonogenetic fetal goiter responding to intra-amniotic thyroxine injections.

Authors:  Selwan Khamisi; Peter Lindgren; F Anders Karlsson
Journal:  Eur Thyroid J       Date:  2014-02-04

Review 2.  Pediatric Hypothyroidism: Diagnosis and Treatment.

Authors:  Ari J Wassner
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

3.  Levothyroxine treatment for congenital hypothyroidism based on thyroid function: a 10-year clinical retrospective study.

Authors:  Shan He; Xiaolin Ma; Jinghui Yang; Li Li
Journal:  BMC Endocr Disord       Date:  2022-05-28       Impact factor: 3.263

4.  Outcome of congenitally hypothyroid screening program in isfahan: iran from prevention to treatment.

Authors:  Mahin Hashemipour; Elham Hashemi Dehkordi; Silva Hovsepian; Massoud Amini; Leila Hosseiny
Journal:  Int J Prev Med       Date:  2010

5.  Free thyroxine level in the high normal reference range prescribed for nonpregnant women may reduce the preterm delivery rate in multiparous.

Authors:  P Torremante; F Flock; W Kirschner
Journal:  J Thyroid Res       Date:  2011-12-12

Review 6.  Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology.

Authors:  Paul van Trotsenburg; Athanasia Stoupa; Juliane Léger; Tilman Rohrer; Catherine Peters; Laura Fugazzola; Alessandra Cassio; Claudine Heinrichs; Veronique Beauloye; Joachim Pohlenz; Patrice Rodien; Regis Coutant; Gabor Szinnai; Philip Murray; Beate Bartés; Dominique Luton; Mariacarolina Salerno; Luisa de Sanctis; Mariacristina Vigone; Heiko Krude; Luca Persani; Michel Polak
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

7.  Basal Serum Thyroxine Level should Guide Initial Thyroxine Replacement Dose in Neonates with Congenital Hypothyroidism

Authors:  Ceren Günbey; Alev Özön; E Nazlı Gönç; Ayfer Alikaşifoğlu; Sevilay Karahan; Nurgün Kandemir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-12-30

8.  Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study.

Authors:  Gilbert Koch; Britta Steffens; Stephanie Leroux; Verena Gotta; Johannes Schropp; Pascal Gächter; Freya Bachmann; Tatjana Welzel; Marco Janner; Dagmar L'Allemand; Daniel Konrad; Gabor Szinnai; Marc Pfister
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-11       Impact factor: 2.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.